Physician

Mark Andrew Gersman, M.D.

According to 2025 Medicare claims, Mark Gersman, M.D. (NPI: 1205839552) practices ophthalmology in the Canton-Massillon, OH market, with the plurality of this provider's patient population coming from Stark, OH. This provider's primary affiliated billing organization is VITREO-RETINAL CONSULTANTS, INC. (NPI: 1750347662; TIN: 341390523) and primary practice location at 44718-3619. Gersman is affiliated with the IHC Quality Partners, LLC (ACO ID: A2833), participating under the MSSP model.

Gersman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 891 traditional Medicare patients, billed 16,697 HCPCS/CPT codes, and received $1,654,911 in Medicare payments. The top billing code was 67028 (Injection of drug into eye). Part D data shows 477 prescription claims across 176 beneficiaries totaling $12,928 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 29 records totaling $775. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $29,076 and ending at $12,928. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	983	7,102	$1,026,047
2016	1,164	8,653	$1,304,475
2017	1,148	8,919	$1,470,230
2018	1,048	8,165	$1,330,301
2019	1,052	8,103	$1,352,539
2020	889	6,807	$1,147,345
2021	872	6,990	$1,311,191
2022	947	6,894	$1,197,864
2023	1,056	12,093	$1,496,365
2024	891	16,697	$1,654,911

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	163	529	$29,076
2016	166	599	$25,065
2017	166	582	$23,771
2018	135	459	$17,451
2019	143	480	$20,098
2020	112	352	$15,676
2021	135	403	$20,340
2022	129	407	$19,608
2023	193	562	$25,716
2024	176	477	$12,928

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
67028	Injection of drug into eye	347	1,086	$90
92014	Established patient complete exam of visual system	448	563	$83
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	251	680	$63
J3590	Unclassified biologics	161	450	$46
92134	Imaging of retina	798	1,771	$28

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Prednisolone Acetate	Prednisolone Acetate	167	5,837	$5,788
Ketorolac Tromethamine	Ketorolac Tromethamine	61	1,732	$1,605
Ofloxacin	Ofloxacin	63	1,561	$699
Neomycin-Polymyxin-Dexameth	Neomycin/Polymyxin B/Dexametha	59	891	$635
Latanoprost	Latanoprost	43	2,502	$312

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	29	$775	Apellis Pharmaceuticals, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark Andrew Gersman, M.D.?

Tedicare shows public-source Medicare data for Mark Andrew Gersman, M.D. (NPI 1205839552), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Andrew Gersman, M.D. have ACO affiliation data?

Mark Andrew Gersman, M.D. is shown with ACO affiliation data for IHC Quality Partners, LLC (MSSP, ACO ID A2833).

What billing organization is linked to Mark Andrew Gersman, M.D.?

Mark Andrew Gersman, M.D. is linked to VITREO-RETINAL CONSULTANTS, INC. (billing NPI 1750347662) in the available physician profile data.

Does Mark Andrew Gersman, M.D. have Open Payments data?

Mark Andrew Gersman, M.D. has 29 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.